Opus Genetics' Gene Therapy Featured on Good Morning America Amid World Blindness Awareness Month

Strategic Insights -

During World Blindness Awareness Month, Opus Genetics, a clinical-stage biopharmaceutical company, was highlighted on Good Morning America for its pioneering work in developing gene therapies for inherited retinal diseases. The feature story centered around Lindsey Rambo, the second participant in Opus Genetics' ongoing Phase 1/2 trial of gene therapy OPGx-LCA5, aimed at restoring vision in individuals with a rare genetic form of blindness caused by mutations in the LCA5 gene. This milestone marks an unprecedented step forward for the IRD community, showcasing the life-changing potential of gene therapy and the dedication of scientists and patients driving progress.

Key Takeaways:

  • Opus Genetics' gene therapy, OPGx-LCA5, is being developed to restore vision in individuals with inherited retinal diseases caused by mutations in the LCA5 gene.
  • The company's innovative approach involves delivering a functional copy of the defective gene directly to retinal cells using AAV-based gene therapy.
  • The Phase 1/2 trial, featuring Lindsey Rambo as the second participant, is ongoing with the aim of restoring vision for those with inherited retinal diseases.
  • Opus Genetics has received backing from organizations such as the Retinal Degeneration (RD) Fund and the Foundation Fighting Blindness in support of its gene therapy development.
  • The company has multiple ongoing trials for LCA5 and BEST1 gene therapies, and a newly activated site at the Retina Foundation of the Southwest.
  • Opus Genetics is advancing Phentolamine Ophthalmic Solution 0.75%, a partnered therapy for presbyopia and reduced low light vision and nighttime visual disturbances.
  • George Magrath, M.D., Chief Executive Officer of Opus Genetics, emphasized the hope that Opus Genetics and Lindsey's story bring to the IRD community.
  • Lindsey Rambo, the second participant in the Opus Genetics LCA5 trial, expressed hope not just for herself but for others living with inherited blindness.
  • The Good Morning America feature highlights the potential of gene therapy in changing lives and the dedication of patients and researchers driving progress in the fight against inherited blindness.

Statistics:

  • Opus Genetics has multiple ongoing trials for LCA5 and BEST1 gene therapies, indicating a growing clinical and community momentum.
  • The company is advancing Phentolamine Ophthalmic Solution 0.75%, a partnered therapy approved in one indication and being studied in two Phase 3 programs.
  • As of the company's Phase 1/2 trial, Lindsey Rambo is the second participant enrolled.
  • Over 1 million individuals in the United States live with some form of inherited retinal disease, according to Opus Genetics.

Sources:

  • GlobeNewswire: Opus Genetics Featured on Good Morning America for Groundbreaking Gene Therapy Work
  • Opus Genetics: About Us
  • Foundation Fighting Blindness: About Us
  • Retinal Degeneration (RD) Fund: About Us
  • Good Morning America:
  • Opus Genetics: Forward-Looking Statements
  • U.S. Securities and Exchange Commission: Opus Genetics' Filings